Cellebrite Reports Q3 Revenue of $126 Million and Net Income of $20.2 Million

Reuters
11/13
<a href="https://laohu8.com/S/CLBT">Cellebrite</a> Reports Q3 Revenue of $126 Million and Net Income of $20.2 Million

Cellebrite DI Ltd. reported third-quarter 2025 results with annual recurring revenue $(ARR)$ up 19% to $439.8 million and revenue increasing 18% to $126.0 million. Net income reached $20.2 million, while non-GAAP net income was $36.9 million. Adjusted EBITDA was $37.7 million, representing a 29.9% adjusted EBITDA margin. For full-year 2025, Cellebrite expects ARR between $460 million and $475 million, reflecting 16% to 20% annual growth, and revenue between $470 million and $475 million, an annual growth of 17% to 18%. Adjusted EBITDA for the year is projected at $124 million to $127 million, with a margin of 26% to 27%. Recent business highlights include the Autumn 2025 Release, featuring advancements in the Digital Investigation Platform and the announcement of the upcoming Guardian Investigate solution, a SaaS-based investigative tool utilizing agentic AI, scheduled for general availability in early 2026. Subscription-based revenue grew by 21% during the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574177-en) on November 12, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10